sábado, 10 de agosto de 2013

Minireview: The Molecular and Genomic Basis for Prostate Cancer Health Disparities

Minireview: The Molecular and Genomic Basis for Prostate Cancer Health Disparities

  • Minireviews

Minireview: The Molecular and Genomic Basis for Prostate Cancer Health Disparities

  1. Aliccia Bollig-Fischer
- Author Affiliations
  1. Barbara Ann Karmanos Cancer Institute (I.J.P., A.B.-F.); Departments of Urology (I.J.P.) and Oncology (A.B.-F.), Wayne State University School of Medicine (I.J.P., A.B.-F.), Detroit, Michigan 48201
  1. Address all correspondence and requests for reprints to: Isaac J. Powell, 4201 Saint Antoine Street, UHC-7C, Detroit, Michigan 48201. E-mail: ipowell@med.wayne.edu.


Despite more aggressive screening across all demographics and gradual declines in mortality related to prostate cancer (PCa) in the United States, race disparities persist. For African American men (AAM), PCa is more often an aggressive disease showing increased metastases and greater PCa-related mortality compared with European American men. The earliest research points to how distinctions are likely the result of a combination of factors, including ancestry genetics and lifestyle variables. More recent research considers that cancer, although influenced by external forces, is ultimately a disease primarily driven by aberrations observed in the molecular genetics of the tumor. Research studying PCa predominantly from European American men shows that indolent and advanced or metastatic prostate tumors have distinguishing molecular genomic make-ups. Early yet increasing evidence suggests that clinically distinct PCa from AAM also display molecular distinctions. It is reasonable to predict that further study will reveal molecular subtypes and various frequencies for PCa subtypes among diverse patient groups, thereby providing insight as to the genomic lesions and gene signatures that are functionally implicated in carcinogenesis or aggressive PCa in AAM. That knowledge will prove useful in developing strategies to predict who will develop advanced PCa among AAM and will provide the rationale to develop effective individualized treatment strategies to overcome disparities.


  • Abbreviations:
    arrayed comparative genomic hybridization
    African American men
    androgen receptor
    European American men
    epidermal growth factor receptor
    v-ets erythroblastosis virus E26 oncogene homolog
    E-twenty six
    odds ratio
    polycyclic aromatic hydrocarbon
    prostate cancer
    prostate-specific antigen
    radical prostatectomy
    Surveillance, Epidemiology, and End Results
    socio-economic status
    single nucleotide polymorphism
    vitamin D receptor.

  • Received February 13, 2013.
  • Accepted April 16, 2013.

No hay comentarios: